Imaging early changes in proliferation at 1 week post chemotherapy: a pilot study in breast cancer patients with 3′-deoxy-3′-[18F]fluorothymidine positron emission tomography

Kenny, Laura; Coombes, R. Charles; Vigushin, David M.; Al-Nahhas, Adil; Shousha, Sami; Aboagye, Eric O.

doi:10.1007/s00259-007-0379-4

Cited by 251 publications

(209 citation statements)

References 17 publications

Supporting

Mentioning

195

Contrasting

Unclassified

Order By: Relevance

“…Shields et al [34] evaluated an unknown number of lesions in six patients using SUV max and SUV mean (50% threshold technique) and carried out full kinetic analyses (NLR with a b c d Results in breast cancer [15] are also consistent with the present results with reported ICCs of 0.99 and 0.97, and SDs of 11% and 15% for SUV and Patlak K i , respectively. Differences in study design and methods, however, make it difficult to perform a direct comparison.…”

Section: Discussionsupporting

confidence: 87%

“…Unfortunately, NLR3k-derived k 3 showed poor reproducibility. However, both K i and SUV have shown good correlations with other proliferation markers, with K i having the strongest correlation [4,15,33]. The present results indicate that both K i and SUV are reproducible.…”

Section: Discussionmentioning

confidence: 52%

“…To the best of our knowledge, reproducibility of [ 18 F] FLT measurements in malignant tumours has only been assessed in eight patients (nine lesions) with breast cancer [15] and in six patients with NSCLC [34]. Shields et al [34] evaluated an unknown number of lesions in six patients using SUV max and SUV mean (50% threshold technique) and carried out full kinetic analyses (NLR with a b c d Results in breast cancer [15] are also consistent with the present results with reported ICCs of 0.99 and 0.97, and SDs of 11% and 15% for SUV and Patlak K i , respectively.…”

Section: Discussionmentioning

confidence: 99%

“…Recent studies have shown that [ 18 F]FLT PET can predict response to therapy as early as 1 week after treatment [15], and a decrease in [ 18 F]FLT uptake seems to be correlated with prolonged overall survival [16,17].…”

mentioning

confidence: 99%

See 3 more Smart Citations

Reproducibility of quantitative 18F-3′-deoxy-3′-fluorothymidine measurements using positron emission tomography

Langen

Klabbers

Lubberink

et al. 2008

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

Purpose Positron emission tomography (PET) using 18 F-3′-deoxy-3′-fluorothymidine ([ 18 F]FLT) allows noninvasive monitoring of tumour proliferation. For serial imaging in individual patients, good reproducibility is essential. The purpose of the present study was to evaluate the reproducibility of quantitative [ 18 F]FLT measurements. Methods Nine patients with non-small-cell lung cancer (NSCLC) and six with head-and-neck cancer (HNC) underwent [ 18 F]FLT PET twice within 7 days prior to therapy. The maximum pixel value (SUV max ) and a threshold defined volume (SUV 41% ) were defined for all delineated lesions. The plasma to tumour transfer constant (K i ) was estimated using both Patlak graphical analysis and nonlinear regression (NLR). NLR was also used to estimate k 3 , which, at least in theory, selectively reflects thymidine kinase 1 activity. The level of agreement between test and retest values was assessed using the intraclass correlation coefficient (ICC) and Bland-Altman analysis. Results All primary tumours and >90% of clinically suspected locoregional metastases could be delineated. In total, 24 lesions were defined. NLR-derived K i , Patlakderived K i , SUV 41% and SUV max showed excellent reproducibility with ICCs of 0.92, 0.95, 0.98 and 0.93, and SDs of 16%, 12%, 7% and 11%, respectively. Reproducibility was poor for k 3 with an ICC of 0.43 and SD of 38%. Conclusion Quantitative [ 18 F]FLT measurements are reproducible in both NSCLC and HNC patients. When monitoring response in individual patients, changes of more than 15% in SUV 41% , 20-25% in SUV max and Patlak-derived K i , and 32% in NLR3k-derived K i are likely to represent treatment effects.

show abstract

Section: Discussionsupporting

confidence: 87%

Section: Discussionmentioning

confidence: 52%

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

Reproducibility of quantitative 18F-3′-deoxy-3′-fluorothymidine measurements using positron emission tomography

Langen

Klabbers

Lubberink

et al. 2008

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

show abstract

“…70 Early studies on breast cancer have also demonstrated that changes in FLT uptake during treatment predict clinical response, and multicenter trials for breast cancer are ongoing. 71,72 In patients with nonsmall cell lung cancer, a reduction in FLT uptake after 7 days of therapy with gefitinib was highly predictive of tumor response on CT and of progression-free survival. 73 This is a notable result, in that proliferation imaging was effective for predicting response to a biologically targeted agent that often has a cytostatic response when used as monotherapy.…”

Section: Imaging Proliferationmentioning

confidence: 99%

PET/CT imaging in cancer: Current applications and future directions

Farwell

Pryma

Mankoff

2014

Cancer

196

120

View full text Add to dashboard Cite

Positron emission tomography (PET) is a radiotracer imaging method that yields quantitative images of regional in vivo biology and biochemistry. PET, now used in conjunction with computed tomography (CT) in PET/CT devices, has had its greatest impact to date on cancer and is now an important part of oncologic clinical practice and translational cancer research. In this review of current applications and future directions for PET/CT in cancer, the authors first highlight the basic principles of PET followed by a discussion of the biochemistry and current clinical applications of the most commonly used PET imaging agent, 18 F-fluorodeoxyglucose (FDG). Then, emerging methods for PET imaging of other biologic processes relevant to cancer are reviewed, including cellular proliferation, tumor hypoxia, apoptosis, amino acid and cell membrane metabolism, and imaging of tumor receptors and other tumor-specific gene products. The focus of the review is on methods in current clinical practice as well as those that have been translated to patients and are currently in clinical trials. Cancer 2014;120:3433-45.

show abstract

Imaging as a predictor of therapeutic response

Mankoff

Shields

2016

Handbook for Clinical Trials of Imaging and Image‐Guided Interventions

View full text Add to dashboard Cite

Imaging early changes in proliferation at 1 week post chemotherapy: a pilot study in breast cancer patients with 3′-deoxy-3′-[18F]fluorothymidine positron emission tomography

Abstract: [18F]FLT-PET can detect changes in breast cancer proliferation at 1 week after FEC chemotherapy.

Cited by 251 publications

References 17 publications

Reproducibility of quantitative 18F-3′-deoxy-3′-fluorothymidine measurements using positron emission tomography

Reproducibility of quantitative 18F-3′-deoxy-3′-fluorothymidine measurements using positron emission tomography

PET/CT imaging in cancer: Current applications and future directions

Imaging as a predictor of therapeutic response

Contact Info

Product

Resources

About